Literature DB >> 19747494

Swim stress enhances nociceptin/orphanin FQ-induced inhibition of rat dorsal raphe nucleus activity in vivo and in vitro: role of corticotropin releasing factor.

Cristiano Nazzaro1, Mario Barbieri, Katia Varani, Lorenzo Beani, Rita J Valentino, Anna Siniscalchi.   

Abstract

The effects of nociceptin/orphanin FQ on putative serotonin (5HT) neurons of the dorsal raphe nucleus (DRN), known to modulate the behavioral responses to stress, were investigated in vivo and in vitro. In DRN slices from unstressed rats, nociceptin/orphanin FQ concentration-dependently inhibited the firing rate of putative 5HT neurons (EC(50) = 21.6 +/- 1.21 nM) and the selective NOP receptor antagonist UFP-101 shifted the concentration-response curve to the right (estimated pA(2) 6.86). Nociceptin/orphanin FQ potency was enhanced in slices prepared from rats previously subjected to a 15 min swim stress (EC(50) = 1.98 +/- 0.11 nM). Swim stress did not change the number or affinity of NOP receptors in DRN. Stress-elicited potentiation involved corticotropin-releasing factor (CRF)(1) receptors, GABA signaling and protein synthesis, being attenuated by pre-treatment with antalarmin (20 mg/kg, i.p.), diazepam (2.4 mg/kg, i.p.) and cycloheximide (2.5 mg/kg, i.p.), respectively. In anesthetized unstressed rats, locally applied nociceptin/orphanin FQ (0.03 and 0.1 ng/30 nl) inhibited the firing rate of DRN neurons (to 80 +/- 7 and 54 +/- 10% of baseline, respectively). Nociceptin/orphanin FQ inhibition was potentiated both 24 h after swim stress and 1 h after CRF (30 ng/30 nl intra-DRN). Stress-induced potentiation was prevented by the selective CRF(1) receptor antagonist, NBI 30755 (20 mg/kg, i.p.). In contrast, the inhibitory response of DRN neurons to the 5HT(1A) agonist, 8OH-DPAT (1 microg/1 microl, intra-DRN) was not potentiated by swim stress, ruling out a non-specific enhanced permeability of GIRK channel. Together, these findings suggest that CRF and the nociceptin/orphanin FQ/NOP system interact in the DRN during stress to control 5HT transmission; this may play a role in stress-related neuropsychopathologies. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747494      PMCID: PMC2889245          DOI: 10.1016/j.neuropharm.2009.09.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  53 in total

1.  Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist.

Authors:  Stephen C Heinrichs; Errol B De Souza; Gery Schulteis; Jeanette L Lapsansky; Dimitri E Grigoriadis
Journal:  Neuropsychopharmacology       Date:  2002-08       Impact factor: 7.853

Review 2.  Cellular neurophysiological actions of nociceptin/orphanin FQ.

Authors:  T D Moran; F A Abdulla; P A Smith
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

3.  Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus.

Authors:  L G Kirby; K C Rice; R J Valentino
Journal:  Neuropsychopharmacology       Date:  2000-02       Impact factor: 7.853

4.  Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems.

Authors:  K H Skelton; C B Nemeroff; D L Knight; M J Owens
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

Review 5.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

6.  Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins.

Authors:  D K Grammatopoulos; H S Randeva; M A Levine; K A Kanellopoulou; E W Hillhouse
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

7.  Control of glutamate and GABA release by nociceptin/orphanin FQ in the rat lateral amygdala.

Authors:  S Meis; H C Pape
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

8.  Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors.

Authors:  P Celada; M V Puig; J M Casanovas; G Guillazo; F Artigas
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

9.  [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.

Authors:  Girolamo Calo; Anna Rizzi; Daniela Rizzi; Raffaella Bigoni; Remo Guerrini; Giuliano Marzola; Matteo Marti; John McDonald; Michele Morari; David G Lambert; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

10.  Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats.

Authors:  R Ciccocioppo; R Martin-Fardon; F Weiss; M Massi
Journal:  Neuroreport       Date:  2001-05-08       Impact factor: 1.837

View more
  11 in total

Review 1.  A Motivational and Neuropeptidergic Hub: Anatomical and Functional Diversity within the Nucleus Accumbens Shell.

Authors:  Daniel C Castro; Michael R Bruchas
Journal:  Neuron       Date:  2019-05-08       Impact factor: 17.173

Review 2.  Corticotropin releasing hormone and imaging, rethinking the stress axis.

Authors:  Carlo Contoreggi
Journal:  Nucl Med Biol       Date:  2014-11-26       Impact factor: 2.408

Review 3.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

4.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

Review 5.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

6.  Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness.

Authors:  Victor A D Holanda; Iris U Medeiros; Laila Asth; Remo Guerrini; Girolamo Calo'; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2016-04-30       Impact factor: 4.530

7.  Nociceptin receptor antagonist SB 612111 decreases high fat diet binge eating.

Authors:  J Andrew Hardaway; Jennifer Jensen; Michelle Kim; Christopher M Mazzone; Jonathan A Sugam; Jeffrey F Diberto; Emily G Lowery-Gionta; Lara S Hwa; Kristen E Pleil; Cynthia M Bulik; Thomas L Kash
Journal:  Behav Brain Res       Date:  2016-03-29       Impact factor: 3.332

Review 8.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

9.  Acute Elevations in Cortisol Increase the In Vivo Binding of [11C]NOP-1A to Nociceptin Receptors: A Novel Imaging Paradigm to Study the Interaction Between Stress- and Antistress-Regulating Neuropeptides.

Authors:  Margaret Flanigan; Savannah Tollefson; Michael L Himes; Rehima Jordan; Katherine Roach; Clara Stoughton; Brian Lopresti; N Scott Mason; Roberto Ciccocioppo; Rajesh Narendran
Journal:  Biol Psychiatry       Date:  2019-09-25       Impact factor: 12.810

Review 10.  Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists.

Authors:  Jong Yung Park; Suji Chae; Chang Seop Kim; Yoon Jae Kim; Hyun Joo Yi; Eunjoo Han; Youngshin Joo; Surim Hong; Jae Won Yun; Hyojung Kim; Kyung Ho Shin
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.